Table 9.
Platelet-rich plasma (PRP) compared with control intervention as adjunct treatment for osteoarthritis (non-blinded RCTs).
| LOE | Type of Study | Exp | Cont | Follow-up | Control | Preparation Kit | LR/LP | Plateletconcentration | Number of Inj. | PROM | K-L | Ref | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cerza et al. | I | 2 arms | ACP 60(60) | 60(60) | 24 weeks | HA | ACP (Arthrex) | LP | N/R | 4 | WOMAC | 1–3 | [84] |
| Huang et al. | I | 3 arms | 40(40) | HA 40(40) CS 40(40) |
12 months | HA CS |
N/R | LP | N/R | 4 | WOMAC VAS |
1–2 | [77] |
| Raeissadat et al. (2015) | II | 2 arms | PRP 87(77) | 73(62) | 12 months | HA | Rooyagen Kit | LR | 4.8 ± 1.80 × NPC | 2 | WOMAC SF-36 |
1–4 | [82] |
| Rayegani et al. | I | 2 arms | 32(31) | 33(31) | 6 months | acetaminophen | Rooyagen kit | LR | 5.6 × NPC | 2 | WOMAC SF-36 |
1–4 | [64] |
| Spakova et al. | II | 2 arms | PRP 60 | 60 | 6 months | HA | Labofuge 400R, Heraeus | LR 6.4 ± 2.3 × 103/µL |
680 ± 132 × 106/mL | 3 | WOMAC NRS-11 |
1–3 | [83] |
LOE—level of evidence; exp.—no. of patients receiving treatment in experimental group (no. of patients analyzed at final follow-up); cont.—no. of patients receiving treatment in control group (no. of patients analyzed at final follow-up); LR—leukocyte rich; LP—leukocyte poor; ROM—range of movement; PROM—patient related outcome measures; MRI—magnetic resonance imaging; VAS—visual analog scale; WOMAC—Western Ontario and McMaster Universities Osteoarthritis Index; SF-36—36-Item Short Form Survey; NRS-11—numerical rating scale.